Peter Kaiser - Oct 2, 2024 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Role
Chief Development Officer
Signature
/s/ Donald Notman, Attorney-in-Fact for Peter Kaiser
Stock symbol
OCUL
Transactions as of
Oct 2, 2024
Transactions value $
$0
Form type
4
Date filed
10/4/2024, 05:21 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCUL Common Stock Award $0 +100K +86.22% $0.00 216K Oct 2, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCUL Stock Option (Right to Buy) Award $0 +200K $0.00 200K Oct 2, 2024 Common Stock 200K $9.31 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On October 2, 2024, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, in equal annual installments, beginning on October 1, 2025.
F2 Vests over four years, with 1/48 of the shares vesting monthly beginning on November 1, 2024.